GEN Exclusives

More »

GEN News Highlights

More »
Jul 1, 2009

Morphotek Taps Synageva in Cancer and Infectious Disease Deal

  • Morphotek entered a research agreement with Synageva BioPharma to express and develop therapeutic mAbs for the treatment of various cancers and infectious diseases. The Synageva Expression Platform (SEP™), which is an integrated technology for protein production, processing, and purification, will be used.

    Morphotek’s pipeline includes MORAb-003, or farletuzumab, for ovarian cancer in Phase III, MORAb-009 for pancreatic cancer in Phase II, and MORAb-004 in Phase I trials in solid tumors. “We are always exploring new ways that may enhance the manufacturing process for our antibody products,” states Philip M. Sass, Ph.D., evp and COO, Morphotek.

    Morphotek develops optimized antibodies for therapeutic applications and high-titer manufacturing cell lines using Morphodoma®. The antibodies within the company's pipeline are targeted against antigens licensed from its collaborative partners.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »